Rallybio (RLYB) to Post Quarterly Earnings on Thursday

Posted by Brian Himes on Aug 4th, 2026

Rallybio (NASDAQ:RLYB – Get Free Report) is anticipated to post its results before the market opens on Thursday, August 6th. Analysts expect Rallybio to post earnings of ($1.28) per share and revenue of $0.2160 million for the quarter.

Rallybio (NASDAQ:RLYB – Get Free Report) last posted its quarterly earnings results on Wednesday, May 13th. The company reported ($1.46) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.20) by ($0.26). Rallybio had a negative return on equity of 55.79% and a negative net margin of 911.07%.The company had revenue of $0.21 million during the quarter, compared to analysts’ expectations of $0.21 million.

Rallybio Trading Up 0.1%

NASDAQ:RLYB opened at $15.95 on Tuesday. Rallybio has a 12 month low of $3.20 and a 12 month high of $17.57. The firm has a fifty day simple moving average of $15.92 and a 200-day simple moving average of $11.14. The company has a market capitalization of $84.53 million, a P/E ratio of -3.68 and a beta of -0.90.

Insiders Place Their Bets

In other Rallybio news, major shareholder Adar1 Capital Management, Llc purchased 79,259 shares of Rallybio stock in a transaction on Wednesday, May 13th. The stock was bought at an average cost of $13.99 per share, with a total value of $1,108,833.41. Following the transaction, the insider owned 909,843 shares of the company’s stock, valued at $12,728,703.57. This represents a 9.54% increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In the last 90 days, insiders have purchased 146,568 shares of company stock valued at $2,050,669. 10.30% of the stock is currently owned by corporate insiders.

Institutional Trading of Rallybio

Large investors have recently made changes to their positions in the business. XTX Topco Ltd raised its holdings in shares of Rallybio by 64.6% during the fourth quarter. XTX Topco Ltd now owns 97,313 shares of the company’s stock worth $67,000 after purchasing an additional 38,205 shares during the last quarter. Susquehanna International Group LLP grew its position in Rallybio by 485.9% during the 3rd quarter. Susquehanna International Group LLP now owns 136,294 shares of the company’s stock worth $68,000 after purchasing an additional 113,031 shares during the period. Geode Capital Management LLC grew its position in Rallybio by 1.2% during the 4th quarter. Geode Capital Management LLC now owns 248,005 shares of the company’s stock worth $170,000 after purchasing an additional 2,996 shares during the period. Citadel Advisors LLC raised its stake in shares of Rallybio by 576.1% during the 3rd quarter. Citadel Advisors LLC now owns 438,705 shares of the company’s stock valued at $219,000 after buying an additional 373,821 shares during the last quarter. Finally, Renaissance Technologies LLC raised its stake in shares of Rallybio by 16.9% during the 4th quarter. Renaissance Technologies LLC now owns 835,692 shares of the company’s stock valued at $573,000 after buying an additional 120,892 shares during the last quarter. 90.34% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings restated a “sell (d-)” rating on shares of Rallybio in a research note on Friday, May 8th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, Rallybio currently has a consensus rating of “Sell”.

View Our Latest Analysis on Rallybio

Rallybio Company Profile

(Get Free Report)

Rallybio Therapeutics, Inc (NASDAQ: RLYB) is a clinical‐stage biotechnology company focused on developing and commercializing therapies for people living with rare genetic diseases. The company’s scientific approach leverages diverse modalities—including monoclonal antibodies, small molecules and enzyme replacement—to address high‐unmet‐need conditions in areas such as immunodeficiency, metabolic disorders and dermatologic diseases. Rallybio’s pipeline is designed to advance through registrational clinical trials with the goal of delivering first‐in‐class or best‐in‐class therapies to patients who currently have limited or no approved treatment options.

Among Rallybio’s lead programs is RBX‐100, an investigational therapy for congenital athymia, a rare pediatric immunodeficiency.